Bio Green Med Solution, Inc.(BGMS)

Medical - Pharmaceuticals · Kuala Lumpur, LF

$0.85-0.02 (-2.13%)

Delayed quote: Oct 6, 2026, 11:28 AM EDT

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T15:41:03.673Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:41:03.673Z.

Quote observation: 2026-10-06T15:28:03.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 4,690,985
TTM free cash flow · period ending 2026-06-30: -1,098,000

FMP input reference: c636d25f821ca328dde5756eba65a9b4f657646c0770229dc3782e5e279f5fe4

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BGMS Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

BGMS Competitors' Price/FCF Ratio

BGMS

Bio Green Med Solution, Inc.

Current

Market Cap

$4.69M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CALC

CalciMedica, Inc.

vs BGMS

Market Cap

$4.75M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LEXX

Lexaria Bioscience Corp.

vs BGMS

Market Cap

$4.86M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DRMA

Dermata Therapeutics, Inc.

vs BGMS

Market Cap

$4.55M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PMCB

PharmaCyte Biotech, Inc.

vs BGMS

Market Cap

$4.40M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMNN

Imunon, Inc.

vs BGMS

Market Cap

$5.11M

Price/FCF Ratio

N/A

TTM Avg

15.88

3Y Avg

17.94

5Y Avg

17.94

CLGN

CollPlant Biotechnologies Ltd.

vs BGMS

Market Cap

$4.33M

Price/FCF Ratio

N/A

TTM Avg

63.09

3Y Avg

63.09

5Y Avg

63.09

LIMN

Liminatus Pharma, Inc. Class A Common Stock

vs BGMS

Market Cap

$5.16M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BMGL

Basel Medical Group Ltd Ordinary Shares

vs BGMS

Market Cap

$5.18M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AIDX

20/20 Biolabs Inc.

vs BGMS

Market Cap

$4.20M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Bio Green Med Solution, Inc. (BGMS)	$4.69M	N/A	N/A	N/A	N/A
CalciMedica, Inc. (CALC)vs ›	$4.75M	N/A	N/A	N/A	N/A
Lexaria Bioscience Corp. (LEXX)vs ›	$4.86M	N/A	N/A	N/A	N/A
Dermata Therapeutics, Inc. (DRMA)vs ›	$4.55M	N/A	N/A	N/A	N/A
PharmaCyte Biotech, Inc. (PMCB)vs ›	$4.40M	N/A	N/A	N/A	N/A
Imunon, Inc. (IMNN)vs ›	$5.11M	N/A	15.88	17.94	17.94
CollPlant Biotechnologies Ltd. (CLGN)vs ›	$4.33M	N/A	63.09	63.09	63.09
Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs ›	$5.16M	N/A	N/A	N/A	N/A
Basel Medical Group Ltd Ordinary Shares (BMGL)vs ›	$5.18M	N/A	N/A	N/A	N/A
20/20 Biolabs Inc. (AIDX)vs ›	$4.20M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/FCF Ratio: N/A

BGMS Price/FCF Ratio Metrics

BGMS Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Related Metrics